A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

This study is testing different lengths of time for taking a targeted cancer medication called olaparib, either with or without another drug called bevacizumab. Researchers want to see if taking olaparib for just one year works just as well as taking it for two years for people with certain types of advanced ovarian, fallopian tube, or primary peritoneal cancer.

You might be able to join if you have been newly diagnosed with advanced stage III or IV ovarian cancer of specific types, such as high-grade serous, and have completed your first-line platinum-based chemotherapy successfully. Your doctor or the study team will also check your tumor's genetic profile, including BRCA gene status, to make sure you qualify.

Participants will be assigned to receive either one or two years of maintenance therapy with olaparib, with or without bevacizumab. Throughout the study, you will have regular check-ups, which may include imaging scans like CT or MRI and occasional tissue or fluid samples to monitor your health and how your body responds to the treatment.

This study is currently recruiting participants at multiple locations across the United States, including sites in Alabama and Alaska. Your care team can help you find the most convenient location for your visits.